Janssen

AdvanCell Expands Leadership Team with the Appointment of Christopher Horvath, MS MBA, as Chief Commercial Officer & Chief Operating Officer and Gary Li, PhD, as Chief Strategy Officer

Retrieved on: 
水曜日, 5月 8, 2024
Radiology, Pharmaceutical, Optical, Oncology, Mental Health, Medical Devices, Infectious Diseases, Genetics, Fitness & Nutrition, Clinical Trials, Cardiology, Biotechnology, Alternative Medicine, Health, Practice Management, Managed Care, General Health, Nursing, Medical Supplies, FDA, Diabetes, Surgery, Other Health, Cancer, Commercial, EVP, Johnson & Johnson, Doctor of Philosophy, Janssen, Prostate cancer, SVP, Pfizer, Patient, Translational medicine, Radiopharmaceutical, MBA, Drug discovery, Merck, Management

Chris Horvath, MS, MBA - Chief Commercial and Operating Officer based in Philadelphia.

Key Points: 
  • Chris Horvath, MS, MBA - Chief Commercial and Operating Officer based in Philadelphia.
  • Chris brings nearly two decades of biopharmaceutical oncology expertise spanning drug discovery, commercialization, and corporate leadership, to AdvanCell.
  • Over the past eight years, Chris has been responsible for commercial strategy and leadership, launch preparation and execution, and revenue growth of both clinical-stage and commercial radiopharmaceuticals in oncology.
  • Most recently, at POINT Biopharma, he served as EVP, Commercial and managed cross-functional alliance operations with Lantheus for two clinical-stage assets.

EQS-News: Evotec presents fiscal year 2023 results and announces priority reset to focus on profitable growth

Retrieved on: 
金曜日, 5月 3, 2024
Science, Annual general meeting, EDT, Investment, PIN, Paris Agreement, EVT201, HR, Partnership, Growth, Targets, Insomnia, Webcast, Janssen, Evotec, Novartis, Science Based Targets initiative, Just, Supervisory board, Interim, BMS, Medicine, Capsule

Just – Evotec Biologics contributed € 108.4 m to the total group revenue compared to € 51.3 m in 2022, reflecting a 111% growth.

Key Points: 
  • Just – Evotec Biologics contributed € 108.4 m to the total group revenue compared to € 51.3 m in 2022, reflecting a 111% growth.
  • In March 2023, BMS and Evotec extended and expanded the neurodegeneration partnership, originally signed in 2016, for an additional eight years.
  • Evotec plans to update the market on its mid-term forecast with the release of its H1 2024 results in August 2024.
  • As part of this priority reset and in line with market developments, Evotec will simplify its reporting to Shared R&D and Just – Evotec Biologics starting Q1 2024.

Genmab Announces Financial Results for the First Quarter of 2024

Retrieved on: 
木曜日, 5月 2, 2024
USD, FDA, Pfizer, EDT, Priority review, AbbVie, Food, Risk, Annual report, Johnson & Johnson, DKK, Janssen, U.S. FDA, Risk management, Environment, Rituximab, Follicular lymphoma, Novartis, PDUFA, ADC, Patient, Acquisition, Interim, Lenalidomide, Daratumumab, Priority, BST, Pharmaceutical industry

Genmab is maintaining its 2024 financial guidance published on February 14, 2024.

Key Points: 
  • Genmab is maintaining its 2024 financial guidance published on February 14, 2024.
  • We expect to update our guidance no later than in connection with our second quarter 2024 earnings.
  • Genmab will hold a conference call to discuss the results for the first quarter of 2024 today, Thursday, May 2, at 6:00 pm CEST, 5:00 pm BST or 12:00 pm EDT.
  • Actual results or performance may differ materially from any future results or performance expressed or implied by such statements.

NANOBIOTIX Provides Business Update and Reports Full Year 2023 Financial Results

Retrieved on: 
水曜日, 4月 24, 2024
PFS, CMO, AMF, Cash, Pancreatic cancer, Research, Webcast, Lung, RT, AACR, Lung cancer, EIB, Conference call, Annual report, NBTXR3, ESMO, Conference, Janssen, NSCLC, Monroe Dunaway Anderson, Survival, Johnson & Johnson, Research and development, OS, Therapy, Neoplasm, Clinical trial, Cancer, Esophageal cancer, Immunotherapy, MD, Administration, University, URD, Patient, NANO, MD Anderson Cancer Center, Head, Bank statement, Growth, Pharmaceutical industry

PARIS and CAMBRIDGE, Mass., April 24, 2024 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO - NASDAQ: NBTX - the “Company”), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, provided an update on operational progress and reported financial results for the year ended December 31, 2023, and announced the filing of its universal registration document (URD) for the financial year ended December 31, 2023 with the French financial market authority (Autorité des marchés financiers or AMF), as well as of the Annual Report on Form 20-F for the financial year ended December 31, 2023 with the U.S. Securities and Exchange Commission (SEC).

Key Points: 
  • “2023 was an incredible year of progress for Nanobiotix and our NBTXR3 program.
  • “During 2023, we reported prolonged survival from Study 102 in head and neck cancer further reinforcing the design of our ongoing pivotal NANORAY-312 trial.
  • Cash and Cash Equivalents: As of December 31, 2023, Nanobiotix had €75.3 million in cash and cash equivalents, compared to €41.4 million as of December 31, 2022.
  • During the call, Laurent Levy, chief executive officer, and Bart van Rhijn, chief financial officer, will briefly review the Company’s year-end results and an update on business activities before taking questions from participants.

Cidara Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
月曜日, 4月 22, 2024
CD73, Research, IND, Form, IO, AACR, Fungemia, Immunotherapy, Congress, Annual report, ESMO, Janssen, Tax, DFC, Therapy, SAN, Tavarua, Safety, Annual general meeting, SITC, Collaboration, Caspofungin, Society, Workplace, European, The San Diego Union-Tribune, CDTX, Patient, Bank statement, Pharmaceutical industry

“2023 included significant accomplishments throughout our business within both our Cloudbreak® drug-Fc conjugate (DFC) and our REZZAYO® (rezafungin) programs,” said Jeffrey Stein, Ph.D., president and chief executive officer of Cidara.

Key Points: 
  • “2023 included significant accomplishments throughout our business within both our Cloudbreak® drug-Fc conjugate (DFC) and our REZZAYO® (rezafungin) programs,” said Jeffrey Stein, Ph.D., president and chief executive officer of Cidara.
  • Presented at IDWeek 2023: In October 2023, Cidara presented new preclinical and clinical data on Novel Cloudbreak Influenza Drug-Fc Conjugate CD388 at IDWeek 2023.
  • Net loss for the three months ended December 31, 2023 was $3.2 million, compared to a net loss of $13.6 million for the three months ended December 31, 2022.
  • Net loss for the full year ended December 31, 2023 was $22.9 million, compared to a net loss of $33.6 million for the year ended December 31, 2022.

Seed Health Appoints Microbiome Pioneer Zain Kassam, M.D., M.P.H., as Chief Medical Officer

Retrieved on: 
水曜日, 4月 24, 2024
Western University, Harvard University, Nature Biotechnology, Public health, Chairperson, Abstract, Health, McMaster University, OpenBiome, FMT, Janssen, IPO, Therapy, Science, Ecology, Alumni, Internal medicine, Bacillota, Longevity, Growth, MIT, Medical device

BOSTON, April 24, 2024 /PRNewswire/ -- Seed Health, a microbiome science company, today announced the appointment of Zain Kassam, M.D., M.P.H., as Chief Medical Officer. An award-winning physician-scientist, Dr. Kassam has played a pivotal role in the advancement of microbiome science for over a decade. His extensive body of work includes over 200 peer-reviewed publications and abstracts, including in The New England Journal of Medicine, Nature Biotechnology, and Gastroenterology, and co-authoring international clinical practice guidelines. He has championed more than 30 Phase I-III clinical trials with top-tier academic institutions across multiple therapeutic areas. As Chief Medical Officer, Dr. Kassam will collaborate with Chief Scientific Officer, Dirk Gevers, Ph.D., to oversee Seed Health's R&D portfolio. He will expand the company's gut microbiome program and guide upcoming launches in the vaginal and skin microbiome sectors, as well as in brain health, metabolic health, and longevity.

Key Points: 
  • Dr. Kassam will lead Seed Health's clinical research and medical affairs, driving the
    BOSTON, April 24, 2024 /PRNewswire/ -- Seed Health , a microbiome science company, today announced the appointment of Zain Kassam, M.D., M.P.H., as Chief Medical Officer.
  • As Chief Medical Officer, Dr. Kassam will collaborate with Chief Scientific Officer, Dirk Gevers, Ph.D., to oversee Seed Health's R&D portfolio.
  • He will expand the company's gut microbiome program and guide upcoming launches in the vaginal and skin microbiome sectors, as well as in brain health, metabolic health, and longevity.
  • Before joining Seed Health, Dr. Kassam co-founded and was Chief Medical Officer at two foundational microbiome therapeutics companies, OpenBiome and Finch Therapeutics.

Nowcasting consumer price inflation using high-frequency scanner data: evidence from Germany

Retrieved on: 
火曜日, 4月 23, 2024
Consensus, Online, Cream, Honey, Tax, Glass, MAPI, Consensus Economics, Journal of Economic Perspectives, Milk, Shower, Low-alcohol beer, Autoregressive–moving-average model, Infant, C3, Islam, Wine, Core inflation, Research Papers in Economics, National accounts, Kálmán, Barcode, Journal of International Economics, Communication, Royal Statistical Society, COVID19, Kohl (cosmetics), Natural disaster, Business, Observation, Paper, VAT, European Economic Review, Diebold Nixdorf, Blancmange, Calendar, Sunflower oil, Annual Review of Economics, Hand, C4, DESTATIS, NBER, Tinning, Razor, Forecasting, Gasoline, Coffee, European Economic Association, Cat, Journal of Monetary Economics, Journal of Applied Econometrics, Medeiros, Architecture, Oxford University Press, Producer, GfK, Quarterly Journal of Economics, Margarine, NCBS, Starch, Political economy, Consistency, COVID-19, Consensus decision-making, Website, MIDAS, Behavior, Deutsche Bundesbank, PPI, World Bank, Collection, Medical classification, Orange, Eurozone, Butter, FMCG, Noise, Travel, Clothing, History, Inflation, Liver, International economics, Journal of Political Economy, BSI, OLS, Statistics, Consumer, PDF, University of Chicago, Classification, ECB, Fats, Policy, Multi, WOB, Outline, C6, Mincing, Canadian International Council, Social science, Perfume, University of California, Berkeley, Journal of Forecasting, Federal Reserve Bank, JEL, L1, Journal, Research, Candle, Food, TPD, Credit, Spice, LPG, Janssen, Marmalade, Superior, Literature, Chocolate, Beef, Kiel University, European Central Bank, Natural gas, HICP, Monetary economics, Yogurt, Section 5, ILO, Bermingham, Price, GTIN, Cheese, Macroeconomics, Growth, Beck, XJ, Government, De Beer, Supermarket, Ice cream, Naturally, C53, Corn flakes, BIS, Biscuit, LASSO, Petroleum, A.2, Poultry, Accuracy and precision, Application, White, Lettuce, Risk, ESCB, University of Siegen, OECD, Chapter One, Lipstick, Sack, XT, BIC, Garlic, Consumption, Sokol, Meat, VAR, Database, Section 3, Rusk, American Economic Journal, Royal, Curd, Overalls, Lamb, Great Lockdown, Fruit, Economy, COICOP, International Journal of Forecasting, Aftershave, Section 2, Nonparametric statistics, Attention, Conference, CPI, Heat, Public economics, Common sunflower, Nowcasting, American Economic Review, Computational Statistics (journal), GFK, COVID-19 pandemic, Exercise, Shock, Running, UNECE, Edible, Gambling, Banco, Rigid transformation, European Commission, Frozen, C.2, PRISMA, Official statistics, Concept, Drink, Transaction data, Somatosensory system, Punctuality, Altbier, Food prices, Response, GDP, Index, E31, Cabinet of Germany, Holiday, Machine learning, Series, Green, Whisky, Vegetable, Cola, Journal of Econometrics, Sadik Harchaoui, University, Aggregate, World Bank Group, B.1, Use, Book, Economic statistics, Civil service commission, 1L, Apple, Bread, Filter, Central bank, Brandeis University, Economic Modelling, Bank, Barkan, Roulade, Dairy product, Neural network, Reproduction, IMF, Section, ID, Data, D4L, Cryptocurrency
Key Points: 

    Addex and Perceptive Launch Neurosterix with $63 Million to Accelerate Development of Allosteric Modulator Therapeutics for Neurological Disorders

    Retrieved on: 
    水曜日, 4月 3, 2024
    Discovery, Epilepsy, GABAB, Senior, Glutamic acid, Dyskinesia, Glutamate (neurotransmitter), Drug discovery, Partnership, TBI, SIX, Chronic cough, NAM, CHF5, Therapy, DSM-IV codes, Janssen, Safety, ADX71149, Allosteric regulation, Janssen Pharmaceuticals, Dipraglurant, Research fellow, PAM, Pharmaceutical industry

    With initial funding of $63 million from Perceptive Xontogeny Venture Fund II, with participation from Perceptive Life Sciences Fund and Acorn Bioventures, Neurosterix will acquire a portfolio of preclinical assets and the allosteric modulator drug discovery technology platform from Addex and accelerate their development.

    Key Points: 
    • With initial funding of $63 million from Perceptive Xontogeny Venture Fund II, with participation from Perceptive Life Sciences Fund and Acorn Bioventures, Neurosterix will acquire a portfolio of preclinical assets and the allosteric modulator drug discovery technology platform from Addex and accelerate their development.
    • In return, Addex will receive CHF5 million and a 20% equity interest in Neurosterix.
    • “The launch of Neurosterix in partnership with Perceptive is an important validation of the Addex allosteric modulator drug discovery technology platform and provides the resources to accelerate development of important preclinical assets, including the M4 PAM and mGlu7 negative allosteric modulator (NAM) programs, into the clinic,” said Tim Dyer, CEO of Addex.
    • To guide the launch of Neurosterix, Tim Dyer, in addition to his role at Addex, will assume the role of CEO of Neurosterix.

    Pharmaceutical CDMO Market Size, Share & Trends Analysis Report 2024: Increasing Demand for One-Stop-Shop CDMOs and Orphan Drug Discovery - Global Forecast to 2030 - ResearchAndMarkets.com

    Retrieved on: 
    火曜日, 4月 9, 2024
    Biotechnology, Pharmaceutical, Health, CDMO, Growth, Patient, Knowledge, DSM-IV codes, Cancer, Commercial, Merck & Co., Oncology, Investment, Johnson & Johnson, Janssen, Drug development, API, Patent, Therapy, USD, Fine chemical

    The global pharmaceutical CDMO market size is anticipated to reach USD 235.5 billion by 2030 and it is projected to grow at a CAGR of 7.2% from 2024 to 2030.

    Key Points: 
    • The global pharmaceutical CDMO market size is anticipated to reach USD 235.5 billion by 2030 and it is projected to grow at a CAGR of 7.2% from 2024 to 2030.
    • A growing consumption of biopharmaceuticals, rising demand for advanced therapeutics, demand for orphan drug discovery, upsurge number of clinical trials and increasing demand for one-stop-shop CDMOS are anticipated to influence the global market positively.
    • As pharmaceutical companies invest more in R&D, they may seek external expertise and resources to accelerate drug development processes.
    • CDMOs provide specialized services in drug development, manufacturing, and testing, making them valuable partners for pharmaceutical companies looking to outsource certain aspects of their R&D activities.

    Clearside Biomedical Appoints Victor Chong, M.D., MBA as Chief Medical Officer

    Retrieved on: 
    月曜日, 3月 18, 2024
    DAS, Retina, University, Moorfields Eye Hospital, Pathology, Oligonucleotide, Ranibizumab, Data analysis, Partnership, Business, Boehringer Ingelheim, DME, Patient, Pharming, Research, Royal College of Ophthalmologists, Cell biology, Diabetic retinopathy, C3, University College London, MBA, Eye, Johnson & Johnson, Janssen, Drug development, John Radcliffe Hospital, AMD, CLS, University of Oxford, Royal college, Geographic atrophy, Stargardt disease, DMI, Pharmaceutical industry

    ALPHARETTA, Ga., March 18, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that Victor Chong, M.D., MBA was appointed Chief Medical Officer on March 14, 2024.

    Key Points: 
    • ALPHARETTA, Ga., March 18, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that Victor Chong, M.D., MBA was appointed Chief Medical Officer on March 14, 2024.
    • George Lasezkay, Pharm.D., J.D., President and Chief Executive Officer of Clearside, commented, “Victor is a well-known and well-respected retinal clinician and scientist, who is a strategically focused and visionary leader.
    • We are delighted to have him join the Clearside team.
    • “With the upcoming ODYSSEY data and extensive partnership portfolio, this is an exciting time to join Clearside.